Recent Finacing
Recent Raise
Impact Biomedicines is a San Diego-based biopharmaceutical company developing fedratinib, a selective oral JAK2 inhibitor for myelofibrosis and polycythemia vera.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Impact Biomedicines.
